Giacomo
Tommasi

Senior Associate
The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy. Martin Luther King, Jr.

Giacomo advises Italian and foreign companies in the field of commercial and corporate law, both in relation to extraordinary transactions, such as Venture Capital, Private Equity investments or M&A transactions, and in the day-to-day assistance, dealing with the drafting and negotiation of commercial agreements, as well as with the shareholders’ agreements and corporate governance aspects.

Giacomo joined the Firm in September 2017.
Previously, he collaborated with an Italian law firm specialized in criminal law, where he was involved in the study and drafting of opinions and pleadings, as well as in the legal and jurisprudential research on criminal law matters.
He also collaborated with a law firm dealing with civil law and human rights protection also at international level.

M&A – Private Equity Commercial and corporate Start Up & Venture Capital

You might also be interested in

17.09.2026
Liguria: EUR 10 Million Allocated for Equity and Quasi-Equity Investments in Start ...

Equity and quasi-equity investments for Ligurian startups and micro, small and medium-sized enterprises through public-private co-invest ...

17.09.2026
LCA alongside Quadrivio in the acquisition of Dev4Side Group

Artificial Intelligence PE Fund acquires the Milan-based technology company specialising in AI solutions within the Microsoft ...

05.10.2026
LCA alongside Impresoft in the acquisition of Marketplace Generation and Addiction ...

The group controlled by Clessidra Private Equity strengthens its e-commerce and MarTech offering  

01.10.2026
LCA Studio Legale strengthens the Corporate M&A practice with the arrival of ...

The firm consolidates the practice in extraordinary transactions and in advising Italian and U.S. investors  

25.09.2026
LCA advises the sellers on the sale of 60% of Ecupharma to Adamed Group

Majority stake sold in the Italian pharmaceutical company active in neurology, psychiatry, urology and diabetology